- Home
- ORKA vs NATH Comparison
ORKA vs NATH Comparison
Compare ORKA & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- NATH
- Stock Information
- Founded
- ORKA 2004
- NATH 1916
- Country
- ORKA United States
- NATH United States
- Employees
- ORKA N/A
- NATH N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NATH Restaurants
- Sector
- ORKA Health Care
- NATH Consumer Discretionary
- Exchange
- ORKA Nasdaq
- NATH Nasdaq
- Market Cap
- ORKA 429.4M
- NATH 385.4M
- IPO Year
- ORKA N/A
- NATH N/A
- Fundamental
- Price
- ORKA $8.92
- NATH $92.32
- Analyst Decision
- ORKA Strong Buy
- NATH
- Analyst Count
- ORKA 7
- NATH 0
- Target Price
- ORKA $39.67
- NATH N/A
- AVG Volume (30 Days)
- ORKA 272.6K
- NATH 10.2K
- Earning Date
- ORKA 03-06-2025
- NATH 02-06-2025
- Dividend Yield
- ORKA N/A
- NATH 2.17%
- EPS Growth
- ORKA N/A
- NATH 24.88
- EPS
- ORKA N/A
- NATH 5.80
- Revenue
- ORKA N/A
- NATH $146,386,000.00
- Revenue This Year
- ORKA N/A
- NATH N/A
- Revenue Next Year
- ORKA N/A
- NATH N/A
- P/E Ratio
- ORKA N/A
- NATH $16.52
- Revenue Growth
- ORKA N/A
- NATH 6.83
- 52 Week Low
- ORKA $8.66
- NATH $64.02
- 52 Week High
- ORKA $53.88
- NATH $104.96
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- NATH 43.44
- Support Level
- ORKA N/A
- NATH $88.00
- Resistance Level
- ORKA N/A
- NATH $97.00
- Average True Range (ATR)
- ORKA 0.00
- NATH 2.30
- MACD
- ORKA 0.00
- NATH -0.25
- Stochastic Oscillator
- ORKA 0.00
- NATH 48.00
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.